A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate (Glivec®) Plasmatic Through Level in Patients Newly Diagnosed With Chronic Phase Chronic Myelogenous Leukaemia (CP-CML).
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Imatinib (Primary)
- Indications Myeloid leukaemia
- Focus Therapeutic Use
- Acronyms OPTIMIMATINIB
- 21 Nov 2017 Status changed from active, no longer recruiting to completed.
- 26 Sep 2016 New trial record